Company
Base Therapeutics
Aiming to Edit Disease out of the Genome
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Customers
- broader spectrum of enterprises
Claim, correct or request removal
Record updated 18 September 2026
About
by Advancing the Next Generation of High-Fidelity Gene Editing Technologies and Immune Cell Therapies
Funding snapshot
- Latest round
- Series A2024-09-12
Funding rounds
- Series A
- 2024-09-12
Products
- Other
- AccuBase Gene Editing Technology
- Other
- BASE-NK Cell Therapy
Loading relationship preview